Introduction Heart failure with reduced ejection fraction (HFrEF) causes impaired convective and diffusive oxygen (O2) transport, in part, by nitric oxide -soluble guanylyl cyclase (sGC)- cyclic guanosine monophosphate pathway dysfunction. sGC activators were developed to selectively target oxidized, heme-free sGC and promote vasodilation, thereby demonstrating potential for improving skeletal muscle oxygenation in HFrEF. We tested the hypotheses that 5 days of administration of sGC activator BAY 60-2770 would increase the O2 delivery (Q̇O2)-to-V̇O2 ratio in the skeletal muscle interstitial space (PO2is, pressure driving O2 into the contracting myocyte) of HFrEF rats at rest and during twitch contractions. Methods HFrEF was induced in adult male Sprague-Dawley (3-4 mo. old) rats via myocardial infarction (MI) and the development of HFrEF was monitored via transthoracic echocardiography. Following 3 weeks of HFrEF progression, rats were treated with 0.3 mg/kg of BAY 60-2770 via oral gavage twice per day (HFrEF + BAY; n =10) for 5 days prior to the contraction protocol. The control heart failure group (HFrEF; n = 9) received vehicle only. Phosphorescence quenching protocols determined the partial pressure of O2 in the spinotrapezius muscle interstitial space at rest and during twitch contractions. Results The degree of HFrEF was not different between groups as evidenced by ejection fraction (44.7 ± 5.1 vs. 46.3 ± 4.8%), left ventricular end-diastolic pressure (16 ± 1 vs. 14 ± 1 mmHg), and MI size (29 ± 2 vs. 28 ± 3%) (all P > 0.05) . Despite no difference either at rest or during the contracting steady-state, across the on transient (14-22 seconds of contractions) there was a ~30% increase in PO2is in HFrEF + BAY vs HFrEF (P ≤ 0.05), demonstrating a greater pressure head driving oxygen to the contracting myocyte. There was also a decrease in arterial blood lactate in HFrEF + BAY vs HFrEF (P < 0.05). Conclusions These data support that during the rest-contraction transient, BAY 60-2770 increases PO2is in rats with moderate HFrEF at the transition from rest to exercise, which may speed V̇O2 kinetics, thereby reducing lactate accumulation. This supports sGC activators as a therapeutic targeting vasomotor dysfunction in chronic heart failure which has the potential to increase exercise capacity and quality of life in this patient population.
Read full abstract